Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Finished Goods (2021)

VYNE Therapeutics (VYNE) has disclosed Finished Goods for 1 consecutive years, with $4.0 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Finished Goods changed N/A year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2021, changed N/A, and an annual FY2021 reading of $4.0 million, changed N/A over the prior year.
  • Finished Goods was $4.0 million for Q4 2021 at VYNE Therapeutics.
  • Across five years, Finished Goods topped out at $4.0 million in Q4 2021 and bottomed at $4.0 million in Q4 2021.